The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Montagnana M, Danese E, Ruzzenente V, et al. Clin Chem Lab Med 2011;49:521 -5 Diagnosis of ovarian cancer is often made at an advanced stage when prognosis is poor. Diagnosis is based on invasive procedures (laparoscopy or laparotomy) and inadequate surgical exploration may adversely affect survival. A number of biomarkers have been proposed for diagnosis or screening but few have made it into clinical practice. As with many conditions where a single sensitive and specific marker is unavailable, algorithms using multiple biomarkers in combination with clinical and/or imaging data have been assessed. In this study, Montagnana et al. assessed the Risk of Ovarian Malignancy Algorithm (ROMA) in determining risk of epithelial ovarian cancer (EOC) in women presenting with a pelvic mass.
Diagnosis of ovarian cancer is often made at an advanced stage when prognosis is poor. Diagnosis is based on invasive procedures (laparoscopy or laparotomy) and inadequate surgical exploration may adversely affect survival. A number of biomarkers have been proposed for diagnosis or screening but few have made it into clinical practice. As with many conditions where a single sensitive and specific marker is unavailable, algorithms using multiple biomarkers in combination with clinical and/or imaging data have been assessed. In this study, Montagnana et al. assessed the Risk of Ovarian Malignancy Algorithm (ROMA) in determining risk of epithelial ovarian cancer (EOC) in women presenting with a pelvic mass.
ROMA uses CA125 and human epididymis protein 4 (HE4) concentrations and menopausal status to determine a risk score. In this study, 104 women with a pelvic mass and 49 healthy female controls were enrolled. Receiver operating characteristic (ROC) analyses were used to evaluate ROMA as well as each of the biomarkers alone.
Median CA125 and HE4 concentrations were significantly higher in patients with EOC than healthy controls and those with a benign pelvic mass (both P , 0.0001). HE4 had improved the diagnostic performance over CA125, with an area under the curve (AUC) of 0.77 in premenopausal and 0.94 in postmenopausal women (compared with 0.64 and 0.84, respectively, using CA125). Using ROMA, the AUC was 0.77 and 0.92, respectively.
The limited number of subjects in this study may have affected the results. However, the study highlights an important point -use of an algorithm should be assessed against the component parts alone to determine if its use improves the performance. In this study, HE4 alone performed slightly better than ROMA. Additionally, in the differentiation of EOC and benign pelvic mass, HE4 performed better than CA125. Further investigation is required to determine the value HE4 may have in routine practice.
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Clinical Laboratories, Wishaw General Hospital, Wishaw, UK DOI: 10.1258 DOI: 10. /acb.2011 Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function Endre Z H, Pickering J W, Walker R J, et al. Kidney Int 2011; 79:1119-30 Acute kidney injury (AKI) is a major complication with high mortality in patients admitted to the intensive care unit (ICU). Early diagnosis of AKI is not achievable with plasma creatinine alone.
The authors report a prospective observational study of six urinary biomarkers (g-glutamyltranspeptidase [GGT], alkaline phosphatase [AP], neutrophil-gelatinase-associated lipocalin [NGAL], cystatin C [CysC], kidney injury molecule-1 [KIM-1] and interleukin-18 [IL-18]) as both diagnostic and predictive markers of AKI in a heterogeneous high-risk population.
Comparisons were made using the area under the receiver operating characteristic curve (AUC) for the diagnosis or prediction of AKI, need for dialysis and prediction of mortality at seven days. Data were reassessed after patient stratification by baseline renal function (estimated glomerular filtration rate) and time after renal insult.
Analysis included 528 patients with a mean age of 60 years. The primary diagnoses were variable, including sepsis (19%), cardiac surgery (18%), cardiac arrest (12%) and neurological causes (14%). Over 27% were diagnosed with AKI upon entry to the ICU (plasma creatinine .26.4 mmol/L or .50% above the baseline plasma creatinine concentration).
All biomarkers except AP were diagnostic of AKI, but with low sensitivity (AUC 0.59-0.67, sensitivity 0.27-0.40). CysC, IL-18 and NGAL were the strongest predictors of dialysis (AUC . 0.70) with high negative predictive values. All biomarkers except KIM-1 were predicting mortality within seven days (AUC . 0.60), especially IL-18 (AUC ¼ 0.68).
The performance of all urinary biomarkers was improved by stratification for time after renal insult and baseline renal function before injury. GGT was the only early predictor of AKI within 6 -12 h of insult, whereas CysC and IL-18 showed high predictive values beyond 36 h. In patients with pre-existing renal dysfunction, biomarkers showed limited utility and a delayed detection window (12-36 h after insult), attributed to impaired excretion.
The authors concluded that the high negative predictive value observed for all urinary biomarkers can guide management, but the absence of a high positive predictive value impedes triaging to intervention. The duration of injury and baseline renal function should also be considered when evaluating biomarker performance to diagnose AKI.
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